Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2023 Earnings Call Transcript

But in NIPT is something we’ve been looking at for a long time. We continue to evaluate the space. We continue to evaluate how we can deploy our technology in that space. So Fulgent has ongoing R&D across a lot of areas, NIPT being one of them. So but again, I think, with what we’ve done with carrier screening, with our turnaround time, our ability to interface and integrate some of the clinical advantages we’ve built with Beacon in terms of copy number and dealing with pseudogenes, the proprietary algorithms, I think there’s still a great story to tell to the OB market, even in lieu of having an NIPT test at this time. So Larry, you mentioned — he asked a question about sort of what’s missing to be sort of the full one-stop shop, but I’ll let you take that one.

Lawrence Weiss: Well, I’ll tell you, we recently launched liquid biopsy for solid tumor and we hope to have an HRD test before the end of the year and maybe some additional offerings in 2024.

Andrew Cooper: Great. I’ll stop there. Thanks.

Brandon Perthuis: Thanks, Andrew.

Operator: Thank you. We reached the end of our question-and-answer session. I’d like to turn the floor back over to management for any further or closing comments.

Ming Hsieh: Thank you very much for joining our call today and we are looking forward to update you about our business performance during the next few quarters. Thank you very much.

Operator: Thank you. That does conclude today’s teleconference and webcast. You may disconnect your lines at this time and have a wonderful day. We thank you for your participation today.